-
Published 2/17/2025
Sousa A, Besong OTO, Wachman EM, Taglauer ES, Beane JE, Kefella Y, Koo JS, Saia K, Jones HE, Zhang H. Placental transcriptome analysis in opioid-exposed versus non-opioid exposed pregnancies. Placenta. 2025 Mar 25; 162:27-34. PMID: 39983471.
-
Published 7/1/2024
Khazanchi R, Wachman EM, Schiff DM, Modest A, Saia KA, Hsu HE. Mandatory Child Protective Services Reporting for Substance-Exposed Newborns and Peripartum Outcomes: A Difference-in-Differences Analysis. JAMA Pediatr. 2024 Jul 01; 178(7):719-722. PMID: 38709513.
-
Published 5/21/2024
Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, Werler MM, Carter G, Jones HE, Wachman EM. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Hum Dev. 2024 Jul; 194:106051. PMID: 38815498.
-
Published 2/14/2024
Wachman EM, Saia K, Bressler J, Werler M, Carter G, Jones HE. Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder. J Addict Med. 2024 May-Jun 01; 18(3):288-292. PMID: 38354121.
-
Published 10/1/2023
Harris M, Schiff DM, Saia K, Muftu S, Standish KR, Wachman EM. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023). Breastfeed Med. 2023 Oct; 18(10):715-733. PMID: 37856658.